Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer

SurgiMab

Status and phase: Enrolling; Phase 3

Conditions: Colorectal Neoplasms

Treatments: Drug: SGM-101

Study type: Interventional

Funder types: Industry

Identifiers

NCT03659448

SGM-CLIN03

Details and patient eligibility

About

The performance of SGM-101, an intraoperative imaging agent, will be compared to that of standard "white light" visualization during surgical resections of colorectal cancer.

Full description

The performance of SGM-101, a fluorochrome-labeled anti-carcinoembryonic antigen (CEA) monoclonal antibody intraoperative imaging agent for the delineation of primary and recurrent tumor and metastases in patients undergoing curative surgery for colorectal cancer will be compared to that of standard "white light" visualization in a multicenter, open-label, randomized, controlled, parallel arms clinical study.

Enrollment: 300 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients should be scheduled for curative colorectal cancer surgery of primary cT4 colon cancer or primary cT3/4 rectal cancer, recurrent colorectal cancer or peritoneal metastasized colorectal cancer.
• Female patients must be of non-child-bearing potential (i.e., women with functioning ovaries who have a documented tubal ligation or hysterectomy, ovariectomy or women who are post-menopausal). Women of child-bearing potential will be included provided that they have a negative urine pregnancy test at the day of the injection and agree to practice adequate contraception for 30 days prior to administration of investigational product, and 30 days after completion of injection.

Exclusion criteria

1. Other malignancies, either currently active or diagnosed in the last 5 years, except for adequately treated in situ carcinoma of the cervix and basal or squamous cell skin carcinoma;

2. Primary appendiceal cancer;

3. Laboratory abnormalities defined as:

   • Aspartate AminoTransferase, Alanine AminoTransferase, Gamma Glutamyl Transferase) or Alkaline Phosphatase levels above 5 times the ULN or;
   • Total bilirubin above 2 times the ULN or;
   • Serum creatinine above 1.5 times the ULN or;
   • Absolute neutrophils counts below 1.5 x 109/L or;
   • Platelet count below 100 x 109/L or;
   • Hemoglobin below 4 mmol/L (females) or below 5 mmol/l (males);

4. Known positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAG) or hepatitis C virus (HCV) antibody or patients with untreated serious infections;

5. Any condition that the investigator considers to be potentially jeopardizing the patient's well-being or the study objectives.

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

300 participants in 2 patient groups

Treatment

Active Comparator group

Description:

Patients will receive a single dose of the study drug, SGM-101, and subsequently undergo surgical resections under both "standard "white light" conditions and then NIR.

Treatment:

Drug: SGM-101

No Treatment

No Intervention group

Description:

Patients will not be administered the study drug, SGM-101, and will undergo surgical resections under standard :white light" conditions only.